A pioneering Alzheimer's drug, donanemab, has been rejected for widespread use in the NHS in England, despite its potential to slow down the early stages of the disease. The decision comes from the National Institute of Health and Care Excellence (NICE), which cited concerns over its cost-effectiveness, stating that the drug "does not currently demonstrate value for the NHS."
Donanemab, developed by Eli Lilly, is part of a new class of Alzheimer's drugs, alongside lecanemab, which target the amyloid protein in the brain—one of the causes of Alzheimer's—rather than just managing its symptoms. Clinical trials suggest that donanemab could slow cognitive decline by four to seven months and lead to a 40% reduction in the decline of daily activities. However, NICE pointed out that the benefits were not substantial enough to justify the cost, estimating that the drug is five to six times above what is typically considered acceptable for NHS resources.
This decision follows a similar rejection by NICE of lecanemab in August, despite the Medicines and Healthcare products Regulatory Agency licensing the drug for use in Great Britain. Both drugs have been approved in the United States, though the European Medicines Agency also rejected lecanemab earlier this year.
The rejection raises concerns about a potential two-tier system for Alzheimer's patients where those who can afford the treatment privately will have access, while others reliant on the NHS may be left with nothing.
Both drugs are administered via intravenous drip and carry risks of side effects such as brain swelling and micro brain bleeds.
Source:
Sky News
